Acute Cough in Children
Conditions
Interventions
Two groups:Fluticasone propionate inhaler 250mcg twice per day versus placebo inhaler
Sponsors
Department of Paediatrics, CUHK
Eligibility
Sex/Gender
All
Age
1 Years to 16 Years
Inclusion criteria
Inclusion criteria: 1) Male or female child aged >=18 months and <16 years; 2) Presenting with an acute cough (acute cough defined as cough duration of less than 2 weeks); 3) Provision of written informed consent from parent/legal guardian.
Exclusion criteria
Exclusion criteria: 1) Children who have taken oral or inhaled corticosteroids in the week prior to enrolment; 2) Children who are unable to tolerate inhaled corticosteroids or spacer with or without a mask; 3) Children who have a physician-confirmed underlying chronic respiratory illness; 4) Radiological diagnosis of pneumonia and/or admission to hospital for respiratory illness; 5) Children who are immunocompromised; 6) Children who have cerebral palsy or severe neuro-developmental abnormality.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| 1) Days to resolution of cough;2) Quality of Life scores – PCQOL, Paeds QOL and VAS (To be completed weekly for 4 weeks);3) Scores on the validated cough diary cards (To be completed daily over 4 weeks);4) Incidence of adverse events - unscheduled doctor visits, number of medication doses missed, number;5) Presence of viral infection detected at baseline, day 14 and day 28; | — |
Primary
| Measure | Time frame |
|---|---|
| Good response to ICS treatment defined as a change of 1 in cough VCD score from baseline (average); | — |
Countries
China
Contacts
Public ContactAlbert Martin LI
The Chinese University of Hong Kong
Outcome results
None listed